Earnings summaries and quarterly performance for Scilex Holding.
Executive leadership at Scilex Holding.
Board of directors at Scilex Holding.
Research analysts covering Scilex Holding.
Recent press releases and 8-K filings for SCLX.
Scilex Holding Company's Subsidiary Secures Non-Recourse Loan
SCLX
Debt Issuance
New Projects/Investments
Delisting/Listing Issues
- Scilex Holding Company's wholly-owned subsidiary, SCLX Stock Acquisition JV LLC, entered into a Non-Recourse Loan and Securities Pledge Agreement with The St. James Bank & Trust Company Ltd. on December 16, 2025.
- The agreement provides for a loan of up to $100 million to SCLX JV, with an eight-year maturity date from the initial closing date of the first tranche.
- The loan accrues interest at the 12-month Secured Overnight Financing Rate and requires SCLX JV to pay a 0.25% fee on the principal amount of each tranche.
- As security for the loan, SCLX JV pledged 70% of the aggregate principal amount of the loan in Scilex Holding Company common stock.
- Key events of default include a decrease of more than 20% in the closing price of the pledged securities (if not cured), a decrease of more than 20% in average trading volume, or the delisting of the securities. The lender's recourse for payment is limited to the pledged securities.
Dec 17, 2025, 3:28 PM
Scilex Holding Company Enters $50 Million Non-Recourse Loan Agreement
SCLX
Debt Issuance
- Scilex Holding Company (SCLX) entered into a Non-Recourse Loan and Securities Pledge Agreement with The St. James Bank & Trust Company Ltd. on December 1, 2025.
- The agreement provides for a loan of up to $50 million, accruing interest at the 12-month Secured Overnight Financing Rate plus 2.0% per annum, and includes a 0.25% fee on the principal amount of each tranche.
- The loan is secured by approximately 39.2 million shares of common stock of Datavault AI Inc. held by Scilex.
- The loan is non-recourse, meaning Scilex's liability for payment is limited to the pledged securities.
- Events of default include a decrease of more than 20% in the closing price of the pledged securities (if not cured) or a decrease of more than 20% in their average trading volume, which would increase the interest rate by an additional 5.0% per annum.
Dec 5, 2025, 9:17 PM
Scilex Completes Two-Tranche Equity Financing in Datavault AI Inc.
SCLX
M&A
New Projects/Investments
- Scilex Holding Company (SCLX) completed the second tranche of its strategic investment in Datavault AI Inc. on November 25, 2025, following Datavault AI stockholders' approval on November 24, 2025.
- This tranche involved the purchase and full exercise of a pre-funded warrant for 263,914,094 shares of Datavault AI common stock.
- The shares issued upon exercise have an approximate value of $583.3 million, based on Datavault AI's closing price of $2.21 per share on November 25, 2025.
- The aggregate purchase price for the two-tranche investment was $150 million in Bitcoin (BTC).
- Both companies intend to ramp up collaboration to deliver growth in Real World Asset tokenization in 2026 and beyond.
Dec 1, 2025, 11:15 AM
Scilex Holding Company Secures Exclusive License from DataVault AI for Biotech Data Tokenization
SCLX
New Projects/Investments
Product Launch
- Scilex Holding Company (SCLX) announced on November 4, 2025, that it has in-licensed a worldwide exclusive license from DataVault AI for its AI-driven technology. This license, effective November 3, 2025, is for the tokenization and monetization of Real World Assets (RWA) in genomic, DNA data, diagnosis, therapeutics products, genetic, and drug information within the biotech and biopharma industry.
- The agreement enables Scilex to create and operate a Biotech Exchange platform, which the company believes has the potential to expand into a Pharmaceutical Exchange platform, addressing an estimated $2.0 trillion market opportunity in pharmaceutical drug and diagnostic sales.
- As consideration for the license, Scilex will pay DataVault AI a non-refundable license fee of $10,000,000, payable in four equal installments of $2,500,000 each, with the first due by December 31, 2025.
- Additionally, Scilex has agreed to pay up to an aggregate of $2,550,000,000 in sales milestone payments upon achieving certain net sales for the Licensed Product, and a five-percent (5%) royalty on net sales. The license agreement is subject to earlier termination if Scilex fails to achieve and maintain annual royalty payments of a minimum of $1,000,000 after 24 months from the agreement date.
Nov 4, 2025, 6:21 PM
Scilex Holding Company Enters into Warrant Exercise Agreement and Debt Deferral
SCLX
- On September 30, 2025, Scilex Holding Company entered into a Warrant Exercise Agreement with holders of existing warrants, originally issued on December 11, 2024, to purchase 179,236 shares of common stock at an exercise price of $22.72 per share.
- In exchange for exercising these existing warrants and deferring an amortization payment on Tranche B Notes scheduled for October 1, 2025, the company will issue new warrants (September 2025 Warrants) to purchase an aggregate of 275,000 shares of common stock at an exercise price of $20.00 per share, with an expiration date of December 13, 2029.
- The aggregate gross proceeds from the exercise of the existing warrants, after accounting for a $7.72 per share deferral fee, are approximately $2.7 million.
- Of these proceeds, $2.5 million will be used for the repayment of outstanding amounts under the Tranche B Notes, and the remaining proceeds will be allocated for general corporate purposes.
Oct 1, 2025, 9:14 PM
Scilex Announces $150 Million Strategic Bitcoin Investment in Datavault AI
SCLX
New Projects/Investments
- Scilex Holding Company announced a $150 million strategic Bitcoin investment in Datavault AI Inc..
- This investment aims to provide growth capital to Datavault AI to accelerate its supercomputing infrastructure, expand independent data exchanges, and unlock new revenue streams, particularly in the biotech data monetization market.
- Scilex is expected to receive up to an aggregate of 278,914,094 shares of Datavault common stock at an effective purchase price of $0.5378 per share.
- The initial tranche of the investment, involving 15,000,000 shares of Datavault common stock, closed on September 26, 2025.
- Scilex will also have the right to nominate two directors to Datavault's board for as long as it maintains beneficial ownership of at least 10% of the company's common stock, and one director if ownership is between 5% and 10%.
Sep 26, 2025, 8:10 PM
Scilex Holding Company Exchanges Semnur Stock for Bitcoin
SCLX
New Projects/Investments
M&A
- Scilex Holding Company (SCLX) signed a Securities Purchase Agreement on September 23, 2025, to exchange $200 million of its common stock in its majority-owned subsidiary, Semnur Pharmaceuticals, Inc., for $200 million in Bitcoin (BTC).
- The agreement, which closed on September 25, 2025, involves the sale of 12,500,000 shares of Semnur common stock at $16.00 per share to an institutional investor, Biconomy PTE.LTD.
- Scilex intends to use the proceeds to acquire Bitcoin, establish cryptocurrency treasury operations, and fund investments in other companies, with Biconomy.com providing strategic collaboration.
- The company notes that its cryptocurrency treasury strategy is untested and that the highly volatile nature of digital assets could materially impact its financial condition and share price.
Sep 26, 2025, 8:05 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more